{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:01:40Z","timestamp":1790730100492,"version":"4.1.0"},"reference-count":43,"publisher":"Korean Association of Internal Medicine","issue":"4","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["kjim.org"],"crossmark-restriction":true},"short-container-title":["Korean J Intern Med"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:p>Background\/Aims: Four high-genetic barrier nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB), namely entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and besifovir dipivoxil maleate (BSV), have been established. The aim of this study is to investigate the efficacy of four high-genetic barrier NAs using a network meta-analysis of randomized trials and propensity score-matched cohorts.Methods: Systematic search was performed using PubMed, Cochrane library, and EMBASE and included randomized controlled trials and cohort studies that used propensity score matching. Studies on treatment-na\u00efve CHB patients treated with ETV, TDF, TAF, or BSV were included. Outcomes included alanine aminotransferase normalization and hepatitis B e antigen seroclearance at week 48 and undetectable hepatitis B virus DNA at weeks 48 and 96. Network meta-analysis was performed to synthesize the results.Results: In total, 15,000 patients from 16 studies were included. In terms of 48- and 96-week virologic response (VR), TDF outperformed ETV with statistical significance (48 weeks: odds ratio [OR], 1.38; &lt;i&gt;p&lt;\/i&gt; &lt; 0.001; 96 weeks: OR, 1.57; &lt;i&gt;p&lt;\/i&gt; = 0.004). ETV was ranked first for 48-week biochemical response (BR) and outperformed TDF (OR, 0.76; &lt;i&gt;p&lt;\/i&gt; = 0.028). In the sensitivity analyses, 48-week VR from randomized-controlled trials were compiled, and the same trend toward the superiority of TDF over ETV was found (OR, 1.51; &lt;i&gt;p&lt;\/i&gt; = 0.030).Conclusions: Four high-genetic barrier NAs were compared, and TDF was more likely to achieve a VR after 48 weeks, while ETV provided a superior BR after 48 weeks.<\/jats:p>","DOI":"10.3904\/kjim.2023.311","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T07:31:03Z","timestamp":1718263863000},"page":"577-589","update-policy":"https:\/\/doi.org\/10.3904\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy comparison of high-genetic barrier nucleos(t)ide analogues in treatment-na\u00efve chronic hepatitis B patients: a network meta-analysis"],"prefix":"10.3904","volume":"39","author":[{"given":"Jaejun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pil Soo","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Kew","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-9806","authenticated-orcid":true,"given":"Hyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2270","reference":[{"key":"ref1","volume-title":"","year":"c2022"},{"key":"ref2","first-page":"18035","volume-title":"Hepatitis B virus infection","author":"Yuen","year":"2018"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2007.08.005"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0084"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.11.001"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-017-0596-7"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.02.001"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224773"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2020.00164"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.409"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2016.11.022"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2021.0314"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.026"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.01.004"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"ref21","first-page":"e13983","volume-title":"Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-na\u00efve HBeAg-positive patients with chronic hepatitis B: a large, multicentre, randomized controlled trials","author":"Cai","year":"2019"},{"key":"ref22","first-page":"117","volume-title":"Antiviral curative effects of tenofovir and entecavir in treatment of aged patients with chronic hepatitis B and their regulation on inflammation factors","author":"Zhao","year":"2019"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12902"},{"key":"ref24","first-page":"E161","volume-title":"Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial","author":"Sriprayoon","year":"2017"},{"key":"ref25","first-page":"12329","volume-title":"Clinical efficacy of tenofovir and entecavir in the treatment of chronic hepatitis b infection in patients na\u00efve to nucleosides and their analogues therapy","author":"Zhang","year":"2017"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305138"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15388"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15261"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.637126"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318947"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.025"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4070"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06375-3"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.03.028"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1126-1"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13400"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1590\/s1413-86702012000300006"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13500"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(16)30107-8"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(16)30024-3"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-021-04992-5"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.09.004"}],"container-title":["The Korean Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.kjim.org\/upload\/kjim-2023-311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.kjim.org\/journal\/view.php?doi=10.3904\/kjim.2023.311","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.kjim.org\/upload\/kjim-2023-311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T05:28:51Z","timestamp":1719898131000},"score":1,"resource":{"primary":{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2023.311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.3904\/kjim.2023.311","relation":{},"ISSN":["1226-3303","2005-6648"],"issn-type":[{"value":"1226-3303","type":"print"},{"value":"2005-6648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"2023-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-13","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}